ಠ_ರೃ♡ try DownloadStreamable.com download streamable videos

Pending FDA Approval of Neratinib in HER2+ Breast Cancer

Say and pronounce Pending FDA Approval on SuperTTS.com Make Your Own Text-To-Speech Words Instantly

  Info

Description

Hope S. Rugo, MD, discusses the ExteNET trial, the use of neratinib in the extended adjuvant setting of HER2-positive breast cancer, and how the benefit was particularly impressive for the HER2-positive/ER-positive subgroup.

Tags

cancer oncology
  Email Video to Friends   Receive Emails for Similar Videos

Email:

  Repeat and Loop Video   Link to Video   Create Short URL  Publish Text About This Video   Share on Facebook, Twitter, and more
  See Recommended Videos For You
Old Cartoons on DVD. Visit and Bookmark: Cool90s.com!

Related

  Extended Adjuvant Therapy for HER2-Positive Breast Cancer   FDA Approval in Bladder Cancer, Breakthrough Therapy Designation in DLBCL, and More   Neratinib in HER2+ Breast Cancer   Dr. Blackwell on Neratinib in HER2+ Breast Cancer   Dr. Freedman on Neratinib Plus Capecitabine for CNS Disease from HER2-Positive Breast Cancer   Dr. Kelly on the FDA Approval of Ribociclib in HR+ Breast Cancer   Novartis Metastatic Breast Cancer Treatment   Cancer Advance of the Year, FDA Approval for CINV, Breakthrough Designation in TNBC, And More   FDA Approvals in Breast Cancer and Melanoma, Disappointing Results in HNSCC, and More   FDA Approval in Myeloma, Priority Review in ALL, and 2017 GU Cancers Symposium Highlights   Dr. Pegram on Pertuzumab Plus Trastuzumab and Chemotherapy in Breast Cancer   Brain Metastases in HER2-Positive Breast Cancer   Dr. Tolaney Discusses Neratinib in HER2+ Breast Cancer   Dr. Pegram on Challenges Facing the Treatment of HER2-Positive Breast Cancer   FDA Approves Use of Breast Cancer Treatment Nerlynx   Dr. Pegram on Pertuzumab Combination for HER2-Positive Breast Cancer   FDA Approvals in ALL and Breast Cancer, Priority Reviews in CML and Follicular Lymphoma, and More   Frontline Treatment of ER-Positive Breast Cancer   Dr. Janni on the Benefits of Targeted Therapies for HER2+ Breast Cancer   FDA FDA: Breast implants can cause rare cancer   FDA Approval in ALL, Priority Reviews in CML and Breast Cancer, and More   Dr. Tripathy on Standard and Emerging Treatment Advances for HER2+ Breast Cancer   Dr. Rugo on the Significance of the MONARCH I Trial for Breast Cancer   Study Finds HER2 Breast Cancer Driver In 3 Percent Of Lung Cancers   Clinical Experience: CDK4/6 Inhibitors in Breast Cancer   Review on 2016 FDA Approvals, Halt on AML Trials, and More   Dr. Janni on Challenges Facing the Treatment of HER2-Positive Breast Cancer   HER2-Targeted Therapy in Early Stage HER2+ Breast Cancer   Dr. Janni on the Future of Treatments for HER2-Positive Breast Cancer   Dr. Osborne on the Benefits of Dual-Targeted Therapy for HER2+ Breast Cancer   Dr. Hurvitz on Treatment Options for HER2-Positive Breast Cancer   FDA Approvals in GVHD, CRC, and AML, a Priority Review in MCL, and More   Full FDA Approvals in Breast Cancer and Lung Cancer, Priority Reviews in ALL, and More   Biosimilar Trastuzumab   HER2 Testing in Metastatic Breast Cancer   Dr. Muss on Determining Treatments for HER2+ Breast Cancer   Dr. von Minckwitz on the Safety Profile of the APHINITY Trial for HER2+ Breast Cancer   Dr. Kalinsky on Optical Imaging for HER2+ Breast Cancer   Role of Lapatinib in HER2-Positive Breast Cancer   ALTTO Trials Findings For Treating HER2+ Breast Cancer - Mayo Clinic   Dr. DeMichele on the I-SPY2 Trial for HER2+ Breast Cancer   Dr. Yardley on the Results of the APT and APHINITY Trials for HER2+ Breast Cancer   Dr. Barcenas on Colestipol in Management of Neratinib Side Effects in HER2+ Breast Cancer   Dr. Muss on Adjuvant Therapy for Elder Breast Cancer Patients   Dr. Muss on Adjuvant Therapy for Elder Patients with Breast Cancer   Treating HER2+ Metastatic Breast Cancer   Breast Implants Can Cause Rare Cancer, FDA Says   Treating Low-Risk HER2-Positive Breast Cancer   Hollis Youngner's Story - Mayo Clinic Model of Care   Dr. Burstein on the Results of the APT Trial for HER2+ Breast Cancer   Dr. Tolaney on the Current Treatment Landscape for HER2+ Breast Cancer   Dr. Tolaney on the Neoadjuvant Therapy for HER2-Positive Breast Cancer   Pfizer's Experimental Breast Cancer Drug Succeeds In Mid Stage Trial - Stuart Varney   FDA Approval of Ribociclib for Metastatic Breast Cancer   FDA Approval in Carcinoid Syndrome Diarrhea, Priority Reviews in Bladder Cancer and NSCLC, and More   FDA Approval and Priority Review in Ovarian Cancer, End of Part B Payment Model, and More   FDA Approval in Lung Cancer, Priority Reviews in HCC and NHL, and an ODAC Recommendation   Dr. Yardley on the APHINITY Trial for HER2-Positive Breast Cancer   Dr. Freedman on Preventing Brain Metastases in HER2+ Breast Cancer   FDA Acts Against Companies Selling Illegal Cancer Treatments and Clearance on Scalp Cooling System   FDA Approval and 2 Priority Reviews in Bladder Cancer, and ASCO's Cancer Advance of the Year   Dr. Chan on ExteNET Trial for HER2+ Breast Cancer   The FDA Just Approved This New treatment For Metastatic Breast Cancers   Dr. Yee on Phase II ADAPT Trial Results for HER2+/HR+ Breast Cancer   Dr. Hudis on Neoadjuvant Treatment of HER2-Positive Breast Cancer   Dr. Chagpar on Sequencing Therapies for HER2-Positive Breast Cancer   FDA Approvals in NSCLC, Bladder Cancer, and Breast Cancer, and Death in CAR T-cell Therapy Trial   FDA Approval: Frontline Ceritinib for ALK+ NSCLC   Extended Adjuvant Therapy for HER2+ Early Breast Cancer   The FDA Approval of Atezolizumab in Bladder Cancer   Durvalumab FDA Approval for Bladder Cancer   MONARCH 1: Abemaciclib Monotherapy for HR+ mBC   FDA Approvals in CRC, Blood Cancer Detection Diagnostic, and Alopecia, and More   Treatment of HER2-Positive Breast Cancer   FDA Approvals in CRC, Blood Diagnostic, and Alopecia, and More

Popular Today